Blood Plasma Derivatives Global Market Opportunities And Strategies To 2033
상품코드:1486801
리서치사:The Business Research Company
발행일:2024년 05월
페이지 정보:영문 327 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계 혈장 유도체 시장은 2018년 317억 1,270만 달러로 평가되었으며, 2023년까지 연평균 8.0% 이상 성장할 것으로 예상됩니다.
혈우병 유병률 증가
혈우병 유병률 증가는 지금까지 혈장 유도체 시장의 성장을 견인했습니다. 혈우병은 혈액이 제대로 응고되지 않는 것이 특징인 유전성 질환입니다. 이 질환은 일반적으로 유전성이며 주로 남성에게 영향을 미칩니다. 혈장 유도체는 지혈을 회복하고 출혈 에피소드를 효과적으로 예방 또는 치료하는 데 필요한 응고 인자를 제공함으로써 혈우병 관리에 중요한 역할을 합니다. 유전자 재조합 혈액응고인자 제제는 안전성과 공급 안정성이 향상되었지만, 특히 유전자 재조합 제제를 구하기 어려운 지역이나 유전자 재조합 제제에 대한 억제제를 가진 환자에게는 혈장 유래 응고인자가 여전히 중요한 역할을 합니다. 혈장 유래 제제는 혈액 매개 병원체 전파에 대한 우려에도 불구하고 혈장 유래 제제는 혈우병 치료를위한 비용 효율적이고 접근하기 쉬운 옵션을 계속 제공하여 출혈 에피소드의 효과적인 관리와 지혈 회복을 보장합니다. 에 따르면 미국 남성 10만 명당 혈우병 B는 3.7명, 혈우병 A는 12명이었습니다. 또한 미국에서는 남성 출생아 5,617명당 1명, 남성 출생아 19,283명당 1명이 혈우병 B형 혈우병을 앓고 있습니다. 따라서 혈우병 유병률 증가가 혈장 유도체 시장을 견인했습니다.
목차
제1장 주요 요약
혈장 유도체 - 시장의 매력과 거시경제 상황
제2장 목차
제3장 표 리스트
제4장 그래프 리스트
제5장 보고서 구성
제6장 시장 특징
일반적인 시장의 정의
개요
혈장 유도체 시장 정의와 세분화
시장 세분화 : 유형별
알부민
제VIII인자
제IX인자
면역글로불린
첨단 면역글로불린
기타 유형
시장 세분화 : 용도별
혈우병
저감마글로불린 혈증
면역 결핍 질환
폰 빌레브란트병
기타 용도
시장 세분화 : 최종사용자별
병원
클리닉
기타 최종사용자
제7장 주요 시장 동향
제8장 혈장 유도체 시장 : 거시경제 시나리오
COVID-19의 영향 : 혈장 유도체 시장
우크라이나 전쟁의 영향 : 혈장 유도체 시장
고인플레이션의 영향 : 혈장 유도체 시장
제9장 세계 시장 규모와 성장
시장 규모
시장 성장 실적, 2018-2023
시장 성장 촉진요인, 2018-2023
시장 성장 억제요인, 2018-2023
시장 성장 예측, 2023-2028, 2033F
시장 성장 촉진요인, 2023-2028
시장 성장 억제요인, 2023-2028
제10장 세계의 혈장 유도체 시장 : 세분화
세계의 혈장 유도체 시장 : 유형별, 실적과 예측, 2018-2023, 2028F, 2033F
세계의 혈장 유도체 시장 : 용도별, 실적과 예측, 2018-2023, 2028F, 2033F
세계의 혈장 유도체 시장 : 최종사용자별, 실적과 예측, 2018-2023, 2028F, 2033F
제11장 혈장 유도체 시장 : 지역/국가별 분석
세계의 혈장 유도체 시장 : 지역별, 실적과 예측, 2018-2023, 2028F, 2033F
세계의 혈장 유도체 시장 : 국가별, 실적과 예측, 2018-2023, 2028F, 2033F
제12장 아시아태평양 시장
제13장 서유럽 시장
제14장 동유럽 시장
제15장 북미 시장
제16장 남미 시장
제17장 중동 시장
제18장 아프리카 시장
제19장 경쟁 구도와 기업 개요
기업 개요
CSL Limited
China Biologic Products Holdings Inc.
Takeda Pharmaceutical Company Limited
Octapharma AG
Bayer AG
제20장 기타 주요 기업 및 혁신 기업
Kedrion S.p.A.
Bio Products Ltd.
Grifols S.A.
LFB S.A.
ADMA Biologics Inc.
GC Biopharma Corp.
Shanghai Raas Blood Products Co. Ltd.
Emergent BioSolutions Inc.
Biotest AG
SK Plasma Co., Ltd.
BioreclamationIVT
Fusion Health Care Pvt. Ltd.
PlasmaGen BioSciences Private Limited
Cambryn Biologics LLC
Sanquin Innovation B.V.
제21장 경쟁 벤치마킹
제22장 경쟁 대시보드
제23장 주요 인수합병(M&A)
Pfizer Inc. Acquired Blood Therapeutics Inc.
Grifols S.A. Acquired Biotest AG
Grifols S.A. Acquired 25 Plasma Centers From BPL Plasma Inc.
Permira Acquired Kedrion Biopharma
Kamada Ltd. Acquired FDA-Licensed Plasma Collection Center From Blood and Plasma Research Inc.
제24장 기회와 전략
세계의 혈장 유도체 시장, 2028년 : 새로운 기회를 제공하는 국가
세계의 혈장 유도체 시장, 2028년 : 새로운 기회를 제공하는 부문
세계의 혈장 유도체 시장, 2028년 : 성장 전략
시장 동향에 근거한 전략
경쟁 전략
제25장 혈장 유도체 시장 : 결론과 제안
결론
제안
제품
장소
가격
프로모션
사람들
제26장 부록
LSH
영문 목차
영문목차
Blood plasma derivatives are medical products derived from human blood plasma. Plasma is the liquid component of blood that remains after cells (red blood cells, white blood cells and platelets) are removed. Plasma derivatives are typically obtained through a process called fractionation, where plasma proteins are separated and purified from the collected plasma.
The blood plasma derivatives market consists of sales, by entities (organizations, sole traders and partnerships), of products derived from the plasma portion of human blood.
The global blood plasma derivatives market was valued at $31,712.7 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 8.0%.
Rise In Hemophilia Prevalence
The rise in hemophilia prevalence drove the growth of the blood plasma derivatives market during this historic period. Hemophilia is a genetic disorder characterized by the inability of the blood to clot properly. This condition is typically inherited and primarily affects males. Blood plasma derivatives play a crucial role in the management of hemophilia by providing the necessary clotting factors to restore hemostasis and prevent or treat bleeding episodes effectively. While recombinant clotting factor products offer enhanced safety profiles and supply stability, plasma-derived factors remain crucial, especially in regions with limited access to recombinant products or for patients with inhibitors against them. Despite concerns regarding blood-borne pathogen transmission, plasma-derived products continue to provide a cost-effective and accessible option for treating hemophilia, ensuring the effective management of bleeding episodes and restoration of hemostasis. In August 2022, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, for every 100,000 American males, there were 3.7 instances of hemophilia B and 12 cases of hemophilia A, respectively. Moreover, it affects 1 in 5,617 male births in the US and 1 in 19,283 male births with hemophilia B. Therefore, the rise in hemophilia prevalence drove the blood plasma derivatives market.
Increasing Investments To Expand Blood Plasma Production Capabilities
Companies in the blood plasma derivatives market are focusing on increasing their investments to capitalize on growth opportunities and contribute to long-term sustainability and profitability. For example, in September 2022, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, invested close to $330 million in expanding its plasma-derived therapy production. This investment aims to enhance access to treatments for rare and complex chronic diseases, such as primary immunodeficiencies and rare conditions like hereditary angioedema and bleeding disorders. Furthermore, in March 2023, CSL Plasma, a US-based plasmapheresis company, invested $470 million to establish a new plasma fractionation facility at its site located in Marburg to expand its production capabilities and enhance its commitment to delivering on its promise to patients.
The global blood plasma derivatives market is fairly concentrated, with a large number of players operating in the market. The top ten competitors in the market made up to 22.6% of the total market in 2022.
Blood Plasma Derivatives Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global blood plasma derivatives market as it emerges from the COVID-19 shut down.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for blood plasma derivatives? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The blood plasma derivatives market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider blood plasma derivatives market; and compares it with other markets.
The report covers the following chapters
Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by application and by end-user.
Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the blood plasma derivatives market.
Global Market Size And Growth- Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
Regional And Country Analysis- Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
Market Segmentation- Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by type, by application and by end-user in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
Regional Market Size and Growth- Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
Competitive Dashboard- Briefs on competitive dashboard of major players.
Key Mergers And Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations-This section includes recommendations for blood plasma derivatives providers in terms of product/service offerings geographic expansion, marketing strategies and target groups next five years.
Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Type: Albumin; Factor VIII; Factor IX; Immunoglobulin; Hyperimmune Globulin; Other Types
2) By Application: Haemophilia; Hypogammaglobulinemia; Immunodeficiency Diseases; Von Willebrand's Disease; Other Application
3) By End-User: Hospitals; Clinics; Other End-Users
Companies Mentioned: CSL Limited; China Biologic Products Holdings Inc.; Takeda Pharmaceutical Company Limited; Octapharma AG; Bayer AG
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; Italy; Spain; UK; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; blood plasma derivatives indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
